Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIO-THREE (TOA Biopharma)
- Development stage
- Unknown
- Lead developer
- TOA Biopharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BIO-THREE is a probiotic formulation developed and manufactured by TOA Biopharma. It contains three symbiotic active bacterial strains: Enterococcus faecium T-110, Clostridium butyricum TO-A, and Bacillus subtilis TO-A. These strains work synergistically to normalize the intestinal flora, promote the growth of beneficial bacteria (such as Bifidobacterium), and inhibit pathogenic microorganisms. Approved as a prescription drug in Japan since 1963, BIO-THREE is indicated for the treatment of gastrointestinal symptoms associated with dysbiosis, including constipation, diarrhea, and abdominal distension. It is also widely used as an over-the-counter (OTC) product, a veterinary feed additive, and a dietary supplement.
- Brand names
- BIO-THREEビオスリー
- Other names
- BIO-THREE probioticBIO-THREE probiotic powder formulationBIOSURI
Beyond the preview
Go deeper on BIO-THREE (TOA Biopharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIO-THREE (TOA Biopharma).